# Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum

> **NCT00580073** · PHASE2 · TERMINATED · sponsor: **University of Wisconsin, Madison** · enrollment: 6 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** FOLFOX4
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00580073
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Loss of funding
- **Last updated:** 2019-12-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00580073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00580073, "Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT00580073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*